Company (Symbol)# (M)
Type Of Financing
Number Of Shares, Units Or Warrants
Amount Raised (M)
Investors; Placement Agents; Details (Date)@
The units were sold at $17,500 each and each consists of 20,000 unregistered shares and 20,000 warrants exercisable for three years at $1.50 per share (7/21)
The shares were sold for $0.40 each and the five-year warrants are exercisable at $0.50 per share, the same terms as the first part of the financing in June that brought in $9.3M (7/13)
Shares in the private placement, primarily with institutional investors, were sold at $3.42 each; the warrants are exercisable at $4.62 per share (7/27)
The 7.07% notes were sold to Baker Brothers Investments and can be converted into common stock at C$5 per share; the deal also includes 0.35 warrants per underlying common share exercisable at C$6.25 per share (7/20)
Corautus closed on a $5M loan from Boston Scientific Corp. under a July 2003 agreement; the loan could increase to up to $15M under the milestone-driven deal (7/26)
Shares in the first tranche of a financing were sold at $5.22 each; the second tranche would include the same number of shares on the same terms; each tranche includes 235,869 warrants exercisable at a 20% premium at the time of the deal (7/7)
The shares were sold at €3 each; Sal. Oppenheim was global coordinator for the financing (7/14)
The warrants in the deal are exercisable at $1.68 per share; the four participating investors have an option to purchase the same number of shares and warrants on the same terms (7/13)
Institutions purchased the shares at $0.50 each and the warrants are exercisable at $1 per share (7/12)
The shares were sold to Novartis Pharma AG in conjunction with Idenix's IPO; the stock was sold at the IPO price of $14 per share; Novartis retained its 57% stake in Idenix through the purchase (7/21)
Each unit consists of one share and one-half of a warrant; each full warrant is convertible for six months into a common share at C$1.55; McFarlane Gordon Inc. and Bieber Securities Inc. were agents for the offering, and received 36,000 warrants exercisable at C$1.25 as part of the deal (7/27)
Ascendiant Securities LLC was placement agent in the deal, which entailed the sale of convertible preferred stock and warrants (7/13)
Norwood Abbey raised $10.1M from the exercise of options that expired June 30 (7/1)
In conjunction with its reacquisition of Estrasorb from King Pharmaceuticals Inc., Novavax sold 4.75% senior convertible notes to institutional investors along with 952,381 common shares at $5.25 per share; the notes are convertible into stock at $6.15 per share (7/19)
This chart does not include real estate or manufacturing plant financings.
# Unless otherwise indicated, shares are traded on the Nasdaq exchange.
@ Dates refer to the date of the press release.
Currencies conversions are based on exchange rates at the time of the deal.
N/A = Not applicable; ND = Not disclosed.
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange.